Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firibastat vs Ramipril to Prevent LV Dysfunction After Acute MI
NCT03715998Phase 2Completed
- Sponsor
- Quantum Genomics
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of firibastat in myocardial infarction (MI) (3 arms), sponsored by Quantum Genomics. Primary endpoint: Left Ventricular Ejection Fraction at 84 days. Started Jun 2019; status: completed.
02
Drugs
firibastat
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03715998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715998.